BS_478TN841
Ganglioglioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Ganglioglioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Ganglioglioma
- overall_survival_months
- 142.27989487516425
- age_years
- 0.742
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.508
- MYOGENESIS+0.506
- TNFA_SIGNALING_VIA_NFKB+0.499
- HEDGEHOG_SIGNALING+0.490
- COAGULATION+0.476
- IL6_JAK_STAT3_SIGNALING+0.472
- INTERFERON_GAMMA_RESPONSE+0.465
- CHOLESTEROL_HOMEOSTASIS+0.463
- INFLAMMATORY_RESPONSE+0.463
- ANGIOGENESIS+0.459
Top 10 suppressed
- E2F_TARGETS-0.617
- G2M_CHECKPOINT-0.597
- MYC_TARGETS_V1-0.577
- OXIDATIVE_PHOSPHORYLATION-0.383
- DNA_REPAIR-0.356
- MITOTIC_SPINDLE-0.328
- PROTEIN_SECRETION-0.296
- UNFOLDED_PROTEIN_RESPONSE-0.196
- SPERMATOGENESIS-0.126
- PI3K_AKT_MTOR_SIGNALING-0.118
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_T55Y4Z0Y | low-grade glioma | — | 0.956 |
| 2 | SRR1797296 | — | cohortMD2 | 0.954 |
| 3 | BS_DSS3S5XD | low-grade glioma | — | 0.951 |
| 4 | BS_EFEZB0ZH | low-grade glioma | — | 0.945 |
| 5 | TCGA-BH-A0BQ-01A-21R-A115-07 | — | A | 0.944 |
| 6 | BS_24AHZ9ZW | low-grade glioma | — | 0.943 |
| 7 | SRR1341702 | GTEX | — | 0.940 |
| 8 | BS_4BWB0FA0 | low-grade glioma | — | 0.940 |
| 9 | BS_044XZ8ST | pilocytic astrocytoma | — | 0.937 |
| 10 | BS_6P50QTPP | low-grade glioma | — | 0.936 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.508 | Inavolisib | — uncovered |
| MYOGENESIS | 0.506 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.499 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.490 | Inavolisib | — uncovered |
| COAGULATION | 0.476 | Binimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.472 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.465 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.463 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.463 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.459 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.451 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.403 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.392 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.386 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.373 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.366 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.363 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.354 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.348 | Inavolisib | — uncovered |
| COMPLEMENT | 0.347 | Inavolisib | — uncovered |